326 related articles for article (PubMed ID: 35456552)
1. An Overview of siRNA Delivery Strategies for Urological Cancers.
Halib N; Pavan N; Trombetta C; Dapas B; Farra R; Scaggiante B; Grassi M; Grassi G
Pharmaceutics; 2022 Mar; 14(4):. PubMed ID: 35456552
[TBL] [Abstract][Full Text] [Related]
2. Potential Application of Small Interfering RNA in Gastro-Intestinal Tumors.
Losurdo P; de Manzini N; Palmisano S; Grassi M; Parisi S; Rizzolio F; Tierno D; Biasin A; Grassi C; Truong NH; Grassi G
Pharmaceuticals (Basel); 2022 Oct; 15(10):. PubMed ID: 36297407
[TBL] [Abstract][Full Text] [Related]
3. Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer.
Ashrafizadeh M; Hushmandi K; Rahmani Moghadam E; Zarrin V; Hosseinzadeh Kashani S; Bokaie S; Najafi M; Tavakol S; Mohammadinejad R; Nabavi N; Hsieh CL; Zarepour A; Zare EN; Zarrabi A; Makvandi P
Bioengineering (Basel); 2020 Aug; 7(3):. PubMed ID: 32784981
[TBL] [Abstract][Full Text] [Related]
4. Strategies to optimize siRNA delivery to hepatocellular carcinoma cells.
Scarabel L; Perrone F; Garziera M; Farra R; Grassi M; Musiani F; Russo Spena C; Salis B; De Stefano L; Toffoli G; Rizzolio F; Tonon F; Abrami M; Chiarappa G; Pozzato G; Forte G; Grassi G; Dapas B
Expert Opin Drug Deliv; 2017 Jun; 14(6):797-810. PubMed ID: 28266887
[TBL] [Abstract][Full Text] [Related]
5. Strategies for Delivery of siRNAs to Ovarian Cancer Cells.
Farra R; Maruna M; Perrone F; Grassi M; Benedetti F; Maddaloni M; El Boustani M; Parisi S; Rizzolio F; Forte G; Zanconati F; Cemazar M; Kamensek U; Dapas B; Grassi G
Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31652539
[TBL] [Abstract][Full Text] [Related]
6. Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles.
Tamura A; Nagasaki Y
Nanomedicine (Lond); 2010 Sep; 5(7):1089-102. PubMed ID: 20874023
[TBL] [Abstract][Full Text] [Related]
7. Strategies for in vivo delivery of siRNAs: recent progress.
Higuchi Y; Kawakami S; Hashida M
BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
[TBL] [Abstract][Full Text] [Related]
8. Environment-Responsive Lipid/siRNA Nanoparticles for Cancer Therapy.
Lu ZR; Laney VEA; Hall R; Ayat N
Adv Healthc Mater; 2021 Mar; 10(5):e2001294. PubMed ID: 33615743
[TBL] [Abstract][Full Text] [Related]
9. Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy.
Mirzaei S; Gholami MH; Ang HL; Hashemi F; Zarrabi A; Zabolian A; Hushmandi K; Delfi M; Khan H; Ashrafizadeh M; Sethi G; Kumar AP
Cells; 2021 Nov; 10(12):. PubMed ID: 34943856
[TBL] [Abstract][Full Text] [Related]
10. Significance and applications of nanoparticles in siRNA delivery for cancer therapy.
Ali HM; Urbinati G; Raouane M; Massaad-Massade L
Expert Rev Clin Pharmacol; 2012 Jul; 5(4):403-12. PubMed ID: 22943120
[TBL] [Abstract][Full Text] [Related]
11. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticles-Based Strategies to Improve the Delivery of Therapeutic Small Interfering RNA in Precision Oncology.
Huang J; Xiao K
Pharmaceutics; 2022 Jul; 14(8):. PubMed ID: 36015212
[TBL] [Abstract][Full Text] [Related]
13. Nanotechnology-Based siRNA Delivery Systems to Overcome Tumor Immune Evasion in Cancer Immunotherapy.
Deng K; Yang D; Zhou Y
Pharmaceutics; 2022 Jun; 14(7):. PubMed ID: 35890239
[TBL] [Abstract][Full Text] [Related]
14. siRNA delivery systems for cancer treatment.
Oh YK; Park TG
Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
[TBL] [Abstract][Full Text] [Related]
15. RNAi-based therapeutics and tumor targeted delivery in cancer.
Kara G; Calin GA; Ozpolat B
Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
[TBL] [Abstract][Full Text] [Related]
16. Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus.
Sohrab SS; El-Kafrawy SA; Mirza Z; Kamal MA; Azhar EI
Curr Pharm Des; 2018; 24(1):62-77. PubMed ID: 29119921
[TBL] [Abstract][Full Text] [Related]
17. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous nanocarrier-mediated delivery of siRNAs and chemotherapeutic agents in cancer therapy and diagnosis: Recent advances.
Bidar N; Darroudi M; Ebrahimzadeh A; Safdari M; de la Guardia M; Baradaran B; Goodarzi V; Oroojalian F; Mokhtarzadeh A
Eur J Pharmacol; 2022 Jan; 915():174639. PubMed ID: 34919890
[TBL] [Abstract][Full Text] [Related]
19. Current progress of siRNA/shRNA therapeutics in clinical trials.
Burnett JC; Rossi JJ; Tiemann K
Biotechnol J; 2011 Sep; 6(9):1130-46. PubMed ID: 21744502
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in siRNA Delivery Systems for Prostate Cancer Therapy.
Aghamiri S; Raee P; Shahmohamadnejad S; Shabani S; Ghorbani J; Sameni M; Ebrahimi MT
Curr Pharm Biotechnol; 2022; 23(4):579-593. PubMed ID: 34132181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
